Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC have jointly announced an agreement for cell line engineering and manufacturing of a monoclonal antibody expressed in a mammalian cell line.
The monoclonal antibody will be engineered by GBI’s collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in clinical trials as a potential treatment for renal cell carcinoma.
“This is an exciting project for us,” noted Muctarr Sesay, PhD, Vice President of Process Development at GBI.
Sesay continued, “It truly represents ‘one-stop-shopping’ for our clients because we can take a client’s cDNA, engineer the cell line with the help of one of our collaborative partners, Rafagen, who will provide us with three stable, high-producing clones, then we’ll evaluate the clones and select the highest producer, create a Research Cell Bank and start manufacturing the antibody of interest.”
“Our drug candidate OM-RCA-001 is a humanized monoclonal antibody and establishing a high producing cell line and creating a cell bank is one of the key stages of the product’s development. We are pleased to partner with GBI in this, since GBI is known for its high quality services in this line of work” said Nikolay Golub, PhD, Project Manager at Maxwell Biotech Group where OncoMax is a portfolio company.
Golub continued, “OM-RCA-001 blocks a specific target of kidney tumor cells, affecting the mechanisms of tumor progression and resistance. If all the clinical trials are successful we will have a novel biopharmaceutical that can be prescribed both as firstline treatment and as treatment in the second and subsequent lines after failure of other types of targeted therapy.”